Cohesic

Name: Cohesic
Address: Suite #A21/6120 2 Street SE, Calgary, AB, T2H2L8, CA
Telephone: +15873272677

A Decision Intelligence Company | We seek cohesion across all points of healthcare data to improve clinical decisions and patient care.

06/05/2026

🫀 New ATTR-CM trial data are reshaping treatment decisions.

Hear experts break down the latest ACC.26 findings and what they mean for therapy selection, patient care, and clinical practice.

🎧 Listen now! https://loom.ly/jPWusvs
⏰ 17 min

06/03/2026

🫀 Can CMR help identify which patients with ICI myocarditis are most at risk for adverse cardiovascular events?

In this prospective study:
• CMR strain abnormalities were common despite preserved LVEF
• 85% met at least one Lake Louise criterion
• LA tissue characterization & strain were associated with arrhythmia, HF, and death
• Serial CMR provided additional prognostic value

As ICI use grows, comprehensive CMR may play an important role in risk stratification and follow-up.

🔗 Read the study: https://loom.ly/KU7qCl4

06/01/2026

🫀 “Your Heart, Your Rhythm, Your Story.”

World Heart Rhythm Week 2026 highlights the importance of recognising arrhythmias earlier, improving diagnosis, and supporting personalised heart rhythm care.

Every rhythm tells a different story — awareness can save lives.
Learn more here! 🔗 https://loom.ly/XLf1JcQ

05/29/2026

World No To***co Day (May 31), led by World Health Organization, highlights the global impact of to***co and ni****ne use, which remains a major contributor to cardiovascular disease worldwide. 🚭

New data are concerning: 40 million children aged 13–15 use to***co products globally, including 15 million using e-cigarettes, and in some regions youth are 9× more likely than adults to v**e. To***co companies continue to market flavoured and “innovative” ni****ne products in ways that may appeal to younger populations!

Learn more about this year’s theme and global resources: https://loom.ly/2btwNc4

***coDay ***coFree

05/27/2026

New ACC/JACC Poster Contribution highlights a systems-based approach to improving cardiac MRI efficiency and access 🫀

Using pathology-driven protocols, structured pre-scan review, and remote scanning support, the team reported a ~38% reduction in scan time alongside expanded service capacity.

An exciting example of how imaging workflows and digital infrastructure intersect in modern cardiovascular care.

Read more here! 🔗 https://loom.ly/QZGIGpo

05/22/2026

Post-CABG NSTE-ACS remains one of the most challenging groups in the cath lab, and practice variation reflects that uncertainty.

In the latest Heart podcast, Prof. James Rudd and Dr Matthew Kelham discuss how CTCA may help reduce unnecessary angiography and better identify patients most likely to benefit from PCI.

The team also discusses the next step: a prospective CTCA-first trial that is now recruiting patients.

🔗 Listen and find the link to the paper here! https://loom.ly/kWfQAgs

05/19/2026

A newly accepted manuscript highlights the potential of accelerated dual-VENC 4D-flow MRI to improve comprehensive flow assessment in complex congenital heart disease (CHD). 🫀

In CHD imaging, clinicians often need to evaluate both high-velocity arterial jets and slow venous circulation within the same examination - a longstanding challenge for conventional single-VENC 4D-flow MRI acquisitions. Dual-VENC approaches aim to expand the measurable velocity range within a single free-breathing scan, with the potential to improve workflow efficiency and hemodynamic assessment.

In this feasibility study, the authors found that low-VENC imaging improved velocity-to-noise ratio and reduced variability in slower venous flows, while high-VENC remained necessary for accurately capturing arterial flow jets. Together, the findings support the feasibility and potential clinical utility of dual-VENC 4D-flow MRI in complex CHD.

🔗 Access more information via EHJ-IMP here! https://loom.ly/9etUXR

05/15/2026

🫀 What happens when AI and clinicians work together in cardiovascular research? Tune into this JACC Author Interviews episode exploring the growing role of AI in supporting faster, scalable cardiovascular research.
🎧 https://loom.ly/pKRXpm0
⏰ 16 mins

05/13/2026

Post hoc analysis from the European Journal of Preventive Cardiology explored whether achieved LDL-C levels after CABG are linked to saphenous vein graft (SVG) patency.

In the NEWTON-CABG CardioLink-5 trial, patients receiving evolocumab evolocumab or placebo showed no difference in overall graft outcomes. However, when looking at achieved LDL-C at 3 months, a clear pattern emerged: lower LDL-C was associated with less SVG occlusion at 2 years, independent of treatment assignment.

Each 1 mmol/L reduction in LDL-C was associated with improved graft patency (OR 0.74, P=0.005).

While post hoc, these findings reinforce a consistent message in post-CABG care—lower achieved LDL-C may translate into better graft outcomes and supports guideline-driven lipid lowering in high-risk patients!

Read the full study in the European Journal of Preventive Cardiology.
🔗 https://loom.ly/fDzuis8

Address

Suite #A21/6120 2 Street SE
Calgary, AB
T2H2L8

Telephone

+15873272677

Website

https://cohesic.com/

Alerts

Be the first to know and let us send you an email when Cohesic posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Cohesic: